Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)
Open Access
- 21 February 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (8), 1479-1481
- https://doi.org/10.1182/blood-2012-12-467415
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Targeted Therapy for Chronic Lymphocytic Leukemia: A Glimpse Into the FutureJournal of Clinical Oncology, 2012
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory DiseaseJournal of Clinical Oncology, 2012
- Focusing on plasma glycoprotein VIThrombosis and Haemostasis, 2012
- Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of plateletsBlood, 2011
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemiaPublished by American Society of Hematology ,2009
- Measuring soluble platelet glycoprotein VI in human plasma by ELISAPlatelets, 2009
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008
- Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemiaBlood, 2008
- Programmed Anuclear Cell Death Delimits Platelet Life SpanCell, 2007
- Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinaseBlood, 2004